Infectious disease specialists

- Support for virology and immunology programs across all development phases
- Leadership in advanced diagnostic testing
- Expertise across viruses including influenza virus, RSV, hMPV, HBV, and SARS‑CoV‑2

Specialized support for infectious disease programs and vaccine and antiviral development, from discovery through clinical development.
We help you turn that complexity into confident action. Acting as an extension of your team, we combine deep expertise in preclinical model development, molecular and cell‑based virology, pathogen biology, immunology, and global clinical execution to support smarter decisions from discovery through late‑phase development, market introduction, post‑marketing (phase IV) trials, and surveillance of resistance to approved interventions.

An overview of our infectious disease expertise.
Our Biosafety Level 3 (BSL–3) laboratories and polio high-containment facility support safe and reliable work on pathogens that require elevated biosafety and/or biosecurity controls.
Specialist teams in our labs support virological and immunological testing for a wide range of infectious diseases caused by viruses, including:
Whether you’re developing vaccines, antivirals, or biologics, we help you better understand immune response, evaluate efficacy, and characterize viral behavior, so you can move forward with confidence at every stage.





Our teams combine virology, immunology, and genomics to generate data that reflects real biological response, helping you assess efficacy, understand mechanisms, and meet regulatory expectations across all phases of development.





We provide consistent, high-quality results across regions through a network of harmonized laboratories and standardized workflows so you can focus on your study outcomes.
Virology: Netherlands (Rotterdam, Rijswijk and Schaijk), Australia (Sydney), France (Frépillon and Montpellier), United States (New York), Canada (Montreal), South Africa (Johannesburg)
Flow cytometry: United States (New York), Belgium (Ghent), Taiwan (Taipei), China (Shanghai), Australia (Sydney)
Genomics: France (Paris), Netherlands, United States (New York and partner lab), Taiwan (Taipei), Canada (Montreal)
Histopathology and IHC: United States (New York), France (Frépillon and Montpellier), Taiwan (Taipei), China (Shanghai)

We apply advanced virology, immunology, molecular, and tissue-based technologies to generate high-quality, regulatory-ready data for infectious disease studies.
Next-generation sequencing (NGS) (Illumina® platforms; Oxford Nanopore Technologies™ sequencing)
Immunoassays and biomarker profiling (ELISA, MSD™ [Meso Scale Discovery], ELLA™, multiplex cytokine profiling up to 37-plex)
Cell-based immune assays (ELISpot and FluoroSpot, ViroSpot™)
Conventional flow cytometry (BD FACSLyric™)
High‑parameter flow cytometry (Cytek® Aurora)
AI-driven analytics for spectral flow cytometry (Ozette)
Spatial biology and transcriptomics (NanoString® GeoMx®, FISH and ISH/RNAscope®)
Digital pathology and image analysis (Indica Labs’ Halo®, Visiopharm®)
In this whitepaper, we explore how to bridge the gap between early scientific questions and robust preclinical experimental design, helping researchers improve translational success, reduce variability, and generate meaningful, decision-ready data.
Learn more about how we can support you, including:


Generate deep immune insights critical to infectious disease research with advanced flow cytometry. Our global network supports immunophenotyping, intracellular cytokine staining, receptor occupancy, and immune activation profiling using cutting-edge spectral platforms.

Accelerate infectious disease programs with integrated preclinical expertise. We support in vivo and ex vivo studies across BSL‑2 and BSL‑3 environments, enabling robust evaluation of vaccine efficacy, antiviral activity, immunogenicity, and safety.

Answer complex immunology questions with fit-for-purpose immunoassays for infectious disease research. We deliver validated and custom ligand-binding assays and multiplex cytokine profiling (up to 37-plex) to support immunogenicity, safety, pharmacokinetics, and neutralizing antibody assessment.

Identify and deploy biomarkers that inform crucial infectious disease outcomes. Our scientists collaborate with you to select, develop, and validate biomarkers that reflect immune activation, inflammation, and protection.

Unlock critical pathogen and host genomic insights with advanced molecular testing. We design and implement molecular assays to support viral load assessment, genotyping, variant tracking, and vaccine‑response characterization.